FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008710391> ?p ?o ?g. }

• W2008710391 endingPage "1009" @default.
• W2008710391 startingPage "1009" @default.
• W2008710391 abstract "Current clinical and immunologic knowledge on cerebellar ataxia (CA) with glutamic acid decarboxylase 65 antibodies (GAD65-Abs) is based on case reports and small series with short-term follow-up data.To report the symptoms, additional antibodies, prognostic factors, and long-term outcomes in a cohort of patients with CA and GAD65-Abs.Retrospective cohort study and laboratory investigations at a center for autoimmune neurologic disorders among 34 patients with CA and GAD65-Abs, including 25 with long-term follow-up data (median, 5.4 years; interquartile range, 3.1-10.3 years).Analysis of clinicoimmunologic features and predictors of response to immunotherapy. Immunochemistry on rat brain, cultured neurons, and human embryonic kidney cells expressing GAD65, GAD67, α1-subunit of the glycine receptor, and a repertoire of known cell surface autoantigens were used to identify additional antibodies. Twenty-eight patients with stiff person syndrome and GAD65-Abs served as controls.The median age of patients was 58 years (range, 33-80 years); 28 of 34 patients (82%) were women. Nine patients (26%) reported episodes of brainstem and cerebellar dysfunction or persistent vertigo several months before developing CA. The clinical presentation was subacute during a period of weeks in 13 patients (38%). Nine patients (26%) had coexisting stiff person syndrome symptoms. Systemic organ-specific autoimmunities (type 1 diabetes mellitus and others) were present in 29 patients (85%). Twenty of 25 patients with long-term follow-up data received immunotherapy (intravenous immunoglobulin in 10 and corticosteroids and intravenous immunoglobulin or other immunosuppressors in 10), and 7 of them (35%) improved. Predictors of clinical response included subacute onset of CA (odds ratio [OR], 0.50; 95% CI, 0.25-0.99; P = .047) and prompt immunotherapy (OR, 0.98; 95% CI, 0.96-0.99; P = .01). Similar frequencies of serum GAD67-Abs were found in patients with CA (24 of 34 patients [71%]) and in patients with stiff person syndrome (20 of 28 patients [71%]). However, GAD67-Abs were found in all of the cerebrospinal fluid samples examined (22 samples from patients with CA and 17 samples from patients with stiff person syndrome). Glycine receptor antibodies but not other cell surface antibodies were identified in 4 patients with CA. The presence of glycine receptor antibodies did not correlate with any specific clinical feature.In patients with CA and GAD65-Abs, subacute onset of symptoms and prompt immunotherapy are associated with good outcome. Persistent vertigo or brainstem and cerebellar episodes can herald CA and should lead to GAD65-Ab testing, particularly in patients with systemic organ-specific autoimmunities." @default.
• W2008710391 created "2016-06-24" @default.
• W2008710391 creator A5000213801 @default.
• W2008710391 creator A5005476543 @default.
• W2008710391 creator A5007841330 @default.
• W2008710391 creator A5014149554 @default.
• W2008710391 creator A5014342106 @default.
• W2008710391 creator A5019663070 @default.
• W2008710391 creator A5021324125 @default.
• W2008710391 creator A5028301912 @default.
• W2008710391 creator A5060042923 @default.
• W2008710391 creator A5060587778 @default.
• W2008710391 creator A5072712902 @default.
• W2008710391 date "2014-08-01" @default.
• W2008710391 modified "2023-10-18" @default.
• W2008710391 title "Cerebellar Ataxia and Glutamic Acid Decarboxylase Antibodies" @default.
• W2008710391 cites W1528905581 @default.
• W2008710391 cites W1969661146 @default.
• W2008710391 cites W1976010346 @default.
• W2008710391 cites W1979645294 @default.
• W2008710391 cites W1980325803 @default.
• W2008710391 cites W1983229413 @default.
• W2008710391 cites W1984098406 @default.
• W2008710391 cites W1987279188 @default.
• W2008710391 cites W1991671146 @default.
• W2008710391 cites W2001974848 @default.
• W2008710391 cites W2003374727 @default.
• W2008710391 cites W2006051208 @default.
• W2008710391 cites W2013484205 @default.
• W2008710391 cites W2017440175 @default.
• W2008710391 cites W2028811447 @default.
• W2008710391 cites W2041602889 @default.
• W2008710391 cites W2042810700 @default.
• W2008710391 cites W2045890664 @default.
• W2008710391 cites W2052985961 @default.
• W2008710391 cites W2054546468 @default.
• W2008710391 cites W2055069215 @default.
• W2008710391 cites W2055296790 @default.
• W2008710391 cites W2065371727 @default.
• W2008710391 cites W2075528611 @default.
• W2008710391 cites W2076409173 @default.
• W2008710391 cites W2076598098 @default.
• W2008710391 cites W2078990452 @default.
• W2008710391 cites W2088872333 @default.
• W2008710391 cites W2089519178 @default.
• W2008710391 cites W2099917041 @default.
• W2008710391 cites W2103856324 @default.
• W2008710391 cites W2110276021 @default.
• W2008710391 cites W2117744349 @default.
• W2008710391 cites W2121816458 @default.
• W2008710391 cites W2123159874 @default.
• W2008710391 cites W2125989828 @default.
• W2008710391 cites W2127043216 @default.
• W2008710391 cites W2152690216 @default.
• W2008710391 cites W2155465367 @default.
• W2008710391 cites W2160211535 @default.
• W2008710391 cites W2161973499 @default.
• W2008710391 cites W2162472632 @default.
• W2008710391 cites W2163022996 @default.
• W2008710391 doi "https://doi.org/10.1001/jamaneurol.2014.1011" @default.
• W2008710391 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4841264" @default.
• W2008710391 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24934144" @default.
• W2008710391 hasPublicationYear "2014" @default.
• W2008710391 type Work @default.
• W2008710391 sameAs 2008710391 @default.
• W2008710391 citedByCount "139" @default.
• W2008710391 countsByYear W20087103912014 @default.
• W2008710391 countsByYear W20087103912015 @default.
• W2008710391 countsByYear W20087103912016 @default.
• W2008710391 countsByYear W20087103912017 @default.
• W2008710391 countsByYear W20087103912018 @default.
• W2008710391 countsByYear W20087103912019 @default.
• W2008710391 countsByYear W20087103912020 @default.
• W2008710391 countsByYear W20087103912021 @default.
• W2008710391 countsByYear W20087103912022 @default.
• W2008710391 countsByYear W20087103912023 @default.
• W2008710391 crossrefType "journal-article" @default.
• W2008710391 hasAuthorship W2008710391A5000213801 @default.
• W2008710391 hasAuthorship W2008710391A5005476543 @default.
• W2008710391 hasAuthorship W2008710391A5007841330 @default.
• W2008710391 hasAuthorship W2008710391A5014149554 @default.
• W2008710391 hasAuthorship W2008710391A5014342106 @default.
• W2008710391 hasAuthorship W2008710391A5019663070 @default.
• W2008710391 hasAuthorship W2008710391A5021324125 @default.
• W2008710391 hasAuthorship W2008710391A5028301912 @default.
• W2008710391 hasAuthorship W2008710391A5060042923 @default.
• W2008710391 hasAuthorship W2008710391A5060587778 @default.
• W2008710391 hasAuthorship W2008710391A5072712902 @default.
• W2008710391 hasBestOaLocation W20087103911 @default.
• W2008710391 hasConcept C118552586 @default.
• W2008710391 hasConcept C119060515 @default.
• W2008710391 hasConcept C126322002 @default.
• W2008710391 hasConcept C181199279 @default.
• W2008710391 hasConcept C203014093 @default.
• W2008710391 hasConcept C2778720950 @default.
• W2008710391 hasConcept C2780148635 @default.
• W2008710391 hasConcept C2780906641 @default.
• W2008710391 hasConcept C55493867 @default.

• next